Biogen and Eisai bail on aducanumab in Alzheimer's Mar. 21, 2019 7:14 AM • SA Editor Douglas W. House
Biogen (NASDAQ:BIIB) and development partner Eisai (OTCPK:ESALY) have decided to terminate two late-stage studies, ENGAGE and EMERGE, evaluating aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia.
The companies decided to pull the plug after a futility analysis showed that the studies were unlikely to meet the primary endpoints.
Certain sell-side analysts were predicting that aducanumab would be a big winner for BIIB.
The data will be submitted for presentation at future medical conferences.
BIIB, current halted, will resume trading at 7:30 am ET.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.